Summary: A new study highlights significant support among healthcare providers for HPV self-collection testing, recently approved by the FDA, which could enhance access to cervical cancer screening.


  1. FDA Approval: On May 15, 2024, the FDA approved patient-collected testing for HPV.
  2. Provider Support: Over half of healthcare providers surveyed would offer HPV self-collection, indicating strong acceptance.
  3. Benefits: Self-collection is particularly beneficial for patients with limited access to clinician-collected screening or those facing barriers to pelvic exams.

In 2019, more than 12,000 new cases of cervical cancer were diagnosed and upwards of 4,000 patients died in the U.S. The causal link between human papillomavirus (HPV) infection and the development of cervical cancer is well documented. Cervical cancer screening guidelines are currently in the review process for updates. On May 15, 2024, the  U.S. Food and Drug Administration (FDA) approved patient-collected testing (vaginal self-collection) for HPV.  Several countries, including the Netherlands and Australia, have introduced HPV self-collection as a part of their national screening programs.

Study Validates HPV Self-Collection

In a new study from Boston University Chobanian & Avedisian School of Medicine and the University of Hawaii at Manoa School of Nursing, researchers found more than half of healthcare providers would definitely or possibly offer HPV self-collection to their patients if the FDA approved the procedure, indicating substantial acceptance of this technology among the healthcare provider community.

“Healthcare providers felt that self-collection would be particularly beneficial for those who did not have access to clinician-collected screening, as well as for patients who may have difficulty with pelvic exams for any reason, such as those with history of trauma, sexual or gender minority patients and those with mobility issues,” explains senior author Rebecca B. Perkins, MD, MSc, professor of obstetrics & gynecology at BU and an obstetrician & gynecologist at Boston Medical Center.

This study incorporated a mixed methods design including conducting a national survey and interviews of healthcare providers who perform cervical cancer screening. Quantitative measures consisted of provider/practice characteristics, willingness to recommend and preferences related to self-collection. Interviews further elucidated the provider perspectives.

Male Physicians More Likely to Support Self-Collection

The study found that male providers, advanced practice providers, internal and family physicians, and those practicing in an academic medical center, hospital, or community health setting were more likely to support self-collection than female participants, OB-GYN physicians, and those in private practice.

“While we found providers considered HPV self-collection to be a way to expand access for patients, they also expressed concerns related to the quality of the sample in generating accurate results,” says Holly Fontenot, PhD, RN/NP, FAAN,professor of nursing at University of Hawaii and lead author of the study.

FDA Approval Provides Better Options

According to the researchers, the recent approval of HPV self-collection in the U.S. provides another option for cervical cancer screening, which can help reduce barriers related to access or to personal medical conditions.

These findings appear online in the journal Women’s Health Issues.

Funding for this study was supported in part by a research grant from American Cancer Society Award RSG19-011-01CPHPC.